These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27797269)

  • 1. Concurrent immunomodulator therapy is associated with higher adalimumab trough levels during scheduled maintenance therapy.
    Bond A; Dodd S; Fisher G; Skouras T; Subramanian S
    Scand J Gastroenterol; 2017 Feb; 52(2):204-208. PubMed ID: 27797269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
    Bond A; Asher R; Jackson R; Sager K; Martin K; Kneebone A; Philips S; Taylor W; Subramanian S
    Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):271-6. PubMed ID: 26657455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
    Strik AS; van den Brink GR; Ponsioen C; Mathot R; Löwenberg M; D'Haens GR
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1128-1134. PubMed ID: 28230306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial.
    Matar M; Shamir R; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Ben-Horin S; Assa A
    Inflamm Bowel Dis; 2020 Oct; 26(11):1627-1635. PubMed ID: 31793630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
    Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.
    Roblin X; Boschetti G; Duru G; Williet N; Deltedesco E; Phelip JM; Peyrin-Biroulet L; Nancey S; Flourié B; Paul S
    Inflamm Bowel Dis; 2017 Nov; 23(11):2048-2053. PubMed ID: 28945636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE
    Scand J Gastroenterol; 2016; 51(4):442-7. PubMed ID: 26595391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Success and safety of high infliximab trough levels in inflammatory bowel disease.
    Drobne D; Kurent T; Golob S; Svegl P; Rajar P; Terzic S; Kozelj M; Novak G; Smrekar N; Plut S; Sever N; Strnisa L; Hanzel J; Brecelj J; Urlep D; Osredkar J; Homan M; Orel R; Stabuc B; Ferkolj I; Smid A
    Scand J Gastroenterol; 2018 Aug; 53(8):940-946. PubMed ID: 29987967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
    Seow CH; Leung Y; Vande Casteele N; Ehteshami Afshar E; Tanyingoh D; Bindra G; Stewart MJ; Beck PL; Kaplan GG; Ghosh S; Panaccione R
    Aliment Pharmacol Ther; 2017 May; 45(10):1329-1338. PubMed ID: 28318043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.
    Drobne D; Bossuyt P; Breynaert C; Cattaert T; Vande Casteele N; Compernolle G; Jürgens M; Ferrante M; Ballet V; Wollants WJ; Cleynen I; Van Steen K; Gils A; Rutgeerts P; Vermeire S; Van Assche G
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):514-521.e4. PubMed ID: 25066841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
    Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.
    Huang VW; Prosser C; Kroeker KI; Wang H; Shalapay C; Dhami N; Fedorak DK; Halloran B; Dieleman LA; Goodman KJ; Fedorak RN
    Inflamm Bowel Dis; 2015 Jun; 21(6):1359-67. PubMed ID: 25989340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.
    Kolho KL; Sipponen T
    Scand J Gastroenterol; 2014 Apr; 49(4):434-41. PubMed ID: 24597837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
    Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
    J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
    Roblin X; Rinaudo M; Del Tedesco E; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Am J Gastroenterol; 2014 Aug; 109(8):1250-6. PubMed ID: 24913041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
    Yanai H; Lichtenstein L; Assa A; Mazor Y; Weiss B; Levine A; Ron Y; Kopylov U; Bujanover Y; Rosenbach Y; Ungar B; Eliakim R; Chowers Y; Shamir R; Fraser G; Dotan I; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):522-530.e2. PubMed ID: 25066837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.
    Ward MG; Warner B; Unsworth N; Chuah SW; Brownclarke C; Shieh S; Parkes M; Sanderson JD; Arkir Z; Reynolds J; Gibson PR; Irving PM
    Aliment Pharmacol Ther; 2017 Jul; 46(2):150-161. PubMed ID: 28481014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
    Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
    Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.